Christopher J. Cassella

Chris Cassella concentrates his practice primarily on complex pharmaceutical patent litigation matters arising under the Hatch-Waxman Amendments to the Patent Act and the Federal Food, Drug and Cosmetic Act. His experience ranges from pre-litigation activities, including Paragraph IV Certifications, through initial filings, fact and expert discovery, claim construction, pre-trial, trial and post-trial phases.

While in law school, in addition to five CALI Excellence for the Future Awards (given to the highest-scoring student in each law school class), Chris earned Brief Writing Honors in the Sherman Minton Moot Court Competition. He also served on the Executive Board of his law school's Intellectual Property Association and was a Senior Editor of the law school's journal, IP Theory. He has an advanced degree in biology as well as an undergraduate degree in biochemistry.

Chris is registered to practice in patent matters before the U.S. Patent and Trademark Office.

His experience includes:

• Representing generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of cystic fibrosis transmembrane conductance regulator potentiator indicated for the treatment of cystic fibrosis
• Representing generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
• Representing generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of a dipeptidyl peptidase-4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• Representing generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of a sodium-glucose cotransporter inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• Representing generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of an antidepressant indicated for the treatment of major depressive disorder
• Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
• Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of a combination of an aromatic amino acid decarboxylation inhibitor and an aromatic amino acid indicated for the treatment of Parkinson's disease
• Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of atypical antipsychotic indicated for the treatment of schizophrenia and depressive episodes associated with Bipolar I Disorder